Palmer RH , Vernersson E , Grabbe C , Hallberg B .

	Figure 1. Domain structure of human ALK and human LTKThe N-terminal region of human ALK (hALK) comprises two MAM domains (amino acids 264–427 and 480–626), one LDLa domain (amino acids 453–471) and a glycine rich (G-rich) region (amino acids 816–940). A transmembrane (TM)-spanning segment, connects the extracellular region with the protein tyrosine kinase (PTK), domain (amino acids 1116–1383)-containing intracellular region. The closest family member, LTK [hLTK (human LTK)], is depicted with the corresponding regions denoted. The signal peptide (amino acids 1–16), the glycine rich, G-rich, domain (amino acids 63–334) and the kinase domain (amino acids 510–777) located in the intracellular C-terminal region of the protein.
	Figure 2. Signalling via ALKSignalling via dALK occurs via binding of the ligand Jeb, downstream activation of ERK and transcription of downstream target genes. Signalling via mammalian ALK is thought to occur via ligand-mediated dimerization in response to the MK and PTN ligands. ALK mediates signalling via the JAK/STAT, RAS/MAPK, PI3K and PLCγ pathways. Activation of ALK via RPTPβ/ζ, independently of direct ALK–ligand interactions has also been proposed. Lastly, ALK is proposed to function as a dependency receptor which is cleaved by caspase 3 (Casp. 3) in the absence of ligand, thereby promoting apoptosis.
	Figure 3. Tyrosine residues phosphorylated in the intracellular regions of human and mouse ALKThe intracellular regions of human and mouse ALK (hALK and mALK respectively) contain the PTK domain. Potential autophosphorylation sites are shown within human and mouse ALK [11]. Note that there is no equivalent tyrosine residue in mouse ALK for human Tyr1604. Tyrosine residues within the activation loop are shown in bold. In italics is a profiling of putative phosphorylated tyrosine residues in NPM–ALK from ALCL cancer cells [166]. Four tyrosine sites, marked with*, have been tested by mutagenesis in NPM–ALK for interaction with signalling proteins such as PLC-γ (Tyr1604 in hALK) [11], Shc (Tyr1507 in hALK) [115], Src (Tyr1358 in hALK) [157], IRS-1 (Tyr1096 in hALK) [115] and SNT (Tyr1096 and Tyr1507 in hALK) [37]. Localization of tyrosine residues within the intracellular region is not to scale. TM, transmembrane domain.

Adam, A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. 2003, Pubmed

Adam, A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. 2003, Pubmed
Ambrogio, The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. 2008, Pubmed
Amin, Pathobiology of ALK+ anaplastic large-cell lymphoma. 2007, Pubmed
Amin, Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. 2004, Pubmed
Amin, Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. 2003, Pubmed
Arber, Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. 1996, Pubmed
Armstrong, Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. 2004, Pubmed
Arora, Role of tyrosine kinase inhibitors in cancer therapy. 2005, Pubmed
Bai, Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. 1998, Pubmed
Bai, Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. 2000, Pubmed
Bassermann, NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. 2005, Pubmed
Bazigou, Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. 2007, Pubmed
Beardsley, Structure and functional relationships in human pur H. 1998, Pubmed
Beckmann, An adhesive domain detected in functionally diverse receptors. 1993, Pubmed
Bernards, The ltk receptor tyrosine kinase is expressed in pre-B lymphocytes and cerebral neurons and uses a non-AUG translational initiator. 1990, Pubmed
Bilsland, Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. 2008, Pubmed
Bischof, Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. 1997, Pubmed
Boccalatte, The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. 2009, Pubmed
Bonvini, Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. 2002, Pubmed
Bowden, Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. 2002, Pubmed
Bridge, Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. 2001, Pubmed
Brodeur, Neuroblastoma: biological insights into a clinical enigma. 2003, Pubmed
Brugières, Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. 2000, Pubmed
Buchdunger, Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. 2000, Pubmed
Buchdunger, Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. 1995, Pubmed
Carén, High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. 2008, Pubmed
Cessna, Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. 2002, Pubmed
Chen, Oncogenic mutations of ALK kinase in neuroblastoma. 2008, Pubmed
Chiarle, Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. 2005, Pubmed
Chiarle, NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. 2003, Pubmed
Chiarle, The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. 2008, Pubmed
Chikamori, Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation. 2007, Pubmed
Choung, [Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement]. 2008, Pubmed
Christensen, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. 2007, Pubmed
Chun, Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. 2005, Pubmed
Coffin, Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. 1995, Pubmed
Coffin, ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. 2001, Pubmed
Coffin, Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. 2007, Pubmed
Colleoni, ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). 2000, Pubmed
Colomba, Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. 2008, Pubmed
Cook, Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. 2001, Pubmed
Cools, Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. 2002, Pubmed
Corao, ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. 2009, Pubmed
Courty, Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. 1991, Pubmed
Crockett, Identification of NPM-ALK interacting proteins by tandem mass spectrometry. 2004, Pubmed
Cussac, Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. 2004, Pubmed
Daly, Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. 1995, Pubmed
De Paepe, ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. 2003, Pubmed
Debelenko, Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. 2003, Pubmed
Debiec-Rychter, ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. 2003, Pubmed
Degoutin, ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. 2009, Pubmed
Degoutin, ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation. 2007, Pubmed
Delsol, A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. 1997, Pubmed
Demetri, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. 2002, Pubmed
Dirks, Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. 2002, Pubmed
Donella-Deana, Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. 2005, Pubmed
Druker, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. 1996, Pubmed
Druker, Translation of the Philadelphia chromosome into therapy for CML. 2008, Pubmed
Du, Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. 2007, Pubmed
Englund, Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. 2003, Pubmed
Englund, Miple1 and miple2 encode a family of MK/PTN homologues in Drosophila melanogaster. 2006, Pubmed
Fabri, Characterization of bovine heparin-binding neurotrophic factor (HBNF): assignment of disulfide bonds. 1992, Pubmed
Falini, ALK+ lymphoma: clinico-pathological findings and outcome. 1999, Pubmed
Fan, Distinct expression of midkine and pleiotrophin in the spinal cord and placental tissues during early mouse development. 2000, Pubmed
Fass, Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module. 1997, Pubmed
Fujimoto, Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). 1996, Pubmed
Fukuyoshi, EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. 2008, Pubmed , Echinobase
Galkin, Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. 2007, Pubmed
Garver, Midkine and pleiotrophin expression in normal and malignant breast tissue. 1994, Pubmed
Gascoyne, Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. 1999, Pubmed
George, Activating mutations in ALK provide a therapeutic target in neuroblastoma. 2008, Pubmed
Gleason, Inflammatory myofibroblastic tumours: where are we now? 2008, Pubmed
Gouzi, Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells. 2005, Pubmed
Graves, The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. 2000, Pubmed
Griffin, Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. 1999, Pubmed
Grzelinski, Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. 2009, Pubmed
Grzelinski, Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. 2005, Pubmed
Gu, NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. 2004, Pubmed
Gunby, An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. 2005, Pubmed
Han, Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. 2006, Pubmed
Hattrup, Structure and function of the cell surface (tethered) mucins. 2008, Pubmed
Hernández, Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. 2002, Pubmed
Hernández, TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. 1999, Pubmed
Herradon, Midkine regulates pleiotrophin organ-specific gene expression: evidence for transcriptional regulation and functional redundancy within the pleiotrophin/midkine developmental gene family. 2005, Pubmed
Hirota, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. 1998, Pubmed
Hudis, Trastuzumab--mechanism of action and use in clinical practice. 2007, Pubmed
Hurley, Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system. 2006, Pubmed
Hübinger, Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma. 2003, Pubmed
Inamura, EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. 2008, Pubmed , Echinobase
Ishihara, HEN-1, a secretory protein with an LDL receptor motif, regulates sensory integration and learning in Caenorhabditis elegans. 2002, Pubmed
Iwahara, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. 1997, Pubmed
Janoueix-Lerosey, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. 2008, Pubmed
Jazii, Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. 2006, Pubmed
Jemal, Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. 2004, Pubmed
Joensuu, Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. 2001, Pubmed
Jäger, Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. 2005, Pubmed
Kadomatsu, Midkine and pleiotrophin in neural development and cancer. 2004, Pubmed
Kamangar, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. 2006, Pubmed
Khoury, Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. 2003, Pubmed
Khoury, Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. 2004, Pubmed
Kilpelainen, Heparin-binding growth-associated molecule contains two heparin-binding beta -sheet domains that are homologous to the thrombospondin type I repeat. 2000, Pubmed
Klapper, The formation of syncytia within the visceral musculature of the Drosophila midgut is dependent on duf, sns and mbc. 2002, Pubmed
Koivunen, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. 2008, Pubmed
Kovesdi, Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins. 1990, Pubmed
Kuefer, Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. 1997, Pubmed
Kuo, Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase. 2007, Pubmed
Lai, Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. 2005, Pubmed
Lamant, Expression of the ALK tyrosine kinase gene in neuroblastoma. 2000, Pubmed
Lamant, A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. 1999, Pubmed
Lamant, Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. 2003, Pubmed
Lamant, Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. 2007, Pubmed
Lange, Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. 2003, Pubmed
Lawrence, TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. 2000, Pubmed
Lee, Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. 2003, Pubmed
Lee, ALK-positive diffuse large B-cell lymphoma: report of three cases. 2008, Pubmed
Leventaki, NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. 2007, Pubmed
Li, Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. 2004, Pubmed
Li, Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. 2006, Pubmed
Li, Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. 2008, Pubmed
Liao, An SCF-like ubiquitin ligase complex that controls presynaptic differentiation. 2004, Pubmed
Lopes, Leukocyte tyrosine kinase functions in pigment cell development. 2008, Pubmed
Lorén, Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo. 2001, Pubmed
Lorén, A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. 2003, Pubmed
Lu, Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. 2005, Pubmed
Ma, Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. 2000, Pubmed
Ma, Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. 2003, Pubmed
Maeda, 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). 1996, Pubmed
Maes, The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. 2001, Pubmed
Maris, Neuroblastoma. 2007, Pubmed
Martelli, EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. 2009, Pubmed , Echinobase
Martin, A distinct set of founders and fusion-competent myoblasts make visceral muscles in the Drosophila embryo. 2001, Pubmed
Marzec, Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. 2007, Pubmed
Marzec, Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. 2007, Pubmed
Marzec, Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. 2005, Pubmed
Mathivet, In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? 2007, Pubmed
Matsumoto, Localization of pleiotrophin and midkine in the postnatal developing cerebellum. 1994, Pubmed
McDermott, Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. 2008, Pubmed
Meech, Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion. 2001, Pubmed
Meng, Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. 2000, Pubmed
Merenmies, Molecular cloning of the 18-kDa growth-associated protein of developing brain. 1990, Pubmed
Mitsiadis, Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. 1995, Pubmed
Miyake, Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. 2002, Pubmed
Momose, Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. 2009, Pubmed
Moog-Lutz, Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. 2005, Pubmed
Morris, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. 1994, Pubmed
Morris, ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). 1997, Pubmed
Mossé, Identification of ALK as a major familial neuroblastoma predisposition gene. 2008, Pubmed
Motegi, ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. 2004, Pubmed
Mourali, Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. 2006, Pubmed
Muramatsu, Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. 2002, Pubmed
Muramatsu, LDL receptor-related protein as a component of the midkine receptor. 2000, Pubmed
Muramatsu, alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor. 2004, Pubmed
Muramatsu, Localization of heparin-binding, neurite outgrowth and antigenic regions in midkine molecule. 1994, Pubmed
Muramatsu, Female infertility in mice deficient in midkine and pleiotrophin, which form a distinct family of growth factors. 2006, Pubmed
Nakamura, Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. 1998, Pubmed
Nakanishi, Expression of syndecan-1 and -3 during embryogenesis of the central nervous system in relation to binding with midkine. 1997, Pubmed
Nieborowska-Skorska, Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. 2001, Pubmed
Okuwaki, The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. 2008, Pubmed
Onciu, ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. 2003, Pubmed
Osajima-Hakomori, Biological role of anaplastic lymphoma kinase in neuroblastoma. 2005, Pubmed
Ouyang, Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). 2003, Pubmed
Paez, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004, Pubmed
Panagopoulos, Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. 2006, Pubmed
Patel, RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. 2007, Pubmed
Perez-Pinera, Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. 2007, Pubmed
Perez-Pinera, Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. 2007, Pubmed
Perner, EML4-ALK fusion lung cancer: a rare acquired event. 2008, Pubmed
Piccinini, A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. 2002, Pubmed
Pillay, ALK protein expression in rhabdomyosarcomas. 2002, Pubmed
Piva, Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. 2006, Pubmed
Piva, Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. 2006, Pubmed
Polgar, Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. 2005, Pubmed
Powers, Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. 2002, Pubmed
Pulford, Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. 1997, Pubmed
Pulford, Anaplastic lymphoma kinase proteins in growth control and cancer. 2004, Pubmed
Qiu, Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. 2006, Pubmed
Rassidakis, Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. 2003, Pubmed
Rassidakis, Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. 2005, Pubmed
Raulo, Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). 1994, Pubmed
Reichard, ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. 2007, Pubmed
Reiner, C. elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-beta signaling. 2008, Pubmed
Riegel, The potential role of the heparin-binding growth factor pleiotrophin in breast cancer. 1994, Pubmed
Rikova, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. 2007, Pubmed
Rush, Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. 2005, Pubmed
Sausville, Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. 2001, Pubmed
Savage, ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. 2008, Pubmed
Schlette, Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. 2004, Pubmed
Shi, JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. 2006, Pubmed
Shinmura, EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. 2008, Pubmed
Shiota, Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. 1994, Pubmed
Shiota, Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. 1995, Pubmed
Shirinian, Drosophila Anaplastic Lymphoma Kinase regulates Dpp signalling in the developing embryonic gut. 2007, Pubmed
Siebert, Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. 1999, Pubmed
Singh, Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. 2009, Pubmed
Sjostrom, Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma. 2007, Pubmed
Slupianek, Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. 2001, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Soda, A mouse model for EML4-ALK-positive lung cancer. 2008, Pubmed
Souttou, Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. 2001, Pubmed
Stachurski, Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24. 2007, Pubmed
Stein, The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. 1985, Pubmed
Stein, CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. 2000, Pubmed
Stoica, Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. 2001, Pubmed
Stoica, Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. 2002, Pubmed
Stute, Myoblast determination in the somatic and visceral mesoderm depends on Notch signalling as well as on milliways(mili(Alk)) as receptor for Jeb signalling. 2004, Pubmed
Takahashi, UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. 1989, Pubmed
Tartari, Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. 2008, Pubmed
Tezuka, Isolation of mouse and human cDNA clones encoding a protein expressed specifically in osteoblasts and brain tissues. 1990, Pubmed
Tomomura, A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product. 1990, Pubmed
Tort, Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. 2001, Pubmed
Touriol, Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). 2000, Pubmed
Trinei, A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. 2000, Pubmed
Trümper, Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals. 1998, Pubmed
Turner, Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. 2003, Pubmed
Turner, What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? 2005, Pubmed
UMIKER, Postinflammatory tumors of the lung; report of four cases simulating xanthoma, fibroma, or plasma cell tumor. 1954, Pubmed
Vanderwinden, Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. 1992, Pubmed
Varshney, The bHLH transcription factor Hand is regulated by Alk in the Drosophila embryonic gut. 2006, Pubmed
Vega, Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. 2006, Pubmed
Vernersson, Characterization of the expression of the ALK receptor tyrosine kinase in mice. 2006, Pubmed
Vigny, Identification of a new heparin-binding protein localized within chick basement membranes. 1989, Pubmed
Voena, The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. 2007, Pubmed
Wan, Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. 2006, Pubmed
Weiss, Jelly belly: a Drosophila LDL receptor repeat-containing signal required for mesoderm migration and differentiation. 2001, Pubmed
Wong, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. 2009, Pubmed , Echinobase
Wu, Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry. 2009, Pubmed
Yamada, Expression of a chimeric CSF1R-LTK mediates ligand-dependent neurite outgrowth. 2008, Pubmed
Yang, The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK. 2007, Pubmed
Zamo, Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. 2002, Pubmed
Zhang, Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. 2002, Pubmed
Zhang, STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. 2007, Pubmed
Zhang, Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. 1997, Pubmed
Zou, Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response. 2006, Pubmed
Zou, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. 2007, Pubmed
ten Berge, Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. 2002, Pubmed
van Oosterom, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. 2001, Pubmed